Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma
Elise A. Chong(Hospital of the University of Pennsylvania), Stephen J. Schuster(Hospital of the University of Pennsylvania), Alfred L. Garfall(University of Pennsylvania), Joseph A. Fraietta(University of Pennsylvania), Guido Ghilardi(Hospital of the University of Pennsylvania), James N. Gerson(UPMC Hillman Cancer Center), Daniel J. Landsburg(University of Pennsylvania), Luca Paruzzo(Hospital of the University of Pennsylvania), David L. Porter(Chapman University), Sunita D. Nasta(University of Pennsylvania), Marco Ruella(Parker Institute for Cancer Immunotherapy), Noelle V. Frey(Hospital of the University of Pennsylvania), Dylan Therwhanger(UPMC Hillman Cancer Center), Natalie Stefano(UPMC Hillman Cancer Center), Jakub Svoboda(UPMC Hillman Cancer Center), Elizabeth Weber(Hospital of the University of Pennsylvania), Stefan K. Barta(University of Pennsylvania)
Cited by 8
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
|American Journal of Hematology|2019|608
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
|Nature Medicine|2021|519